Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

ements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; the potential to enter into and the terms of any commercial partnership or other strategic transaction relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    
    
                          Orexigen Therapeutics, Inc.                         
                         (a development stage company)                        
                            Statements of Operations                          
                    (In thousands, except per share amounts)                  
                                  (Unaudited)                                 
                                                                              
                                                                  Period from 
      
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Privately Test for Hair Loss, LITHIA SPRINGS, ... in professional skincare for the scalp, has,entered into ... world,s first,genetic test for predicting female hair loss. ... the thinning hair category, will market this,test to ...
... that during walking, the ankle does about three times the ... muscles---in other words, the spring in your step is very ... been done measuring the efficiency of individual muscles, this is ... a body part such as the ankle, said Daniel Ferris, ...
... Malaria Day 2008 and despite the grim statistics out ... biologists have discovered an autoimmune-like response in blood drawn ... existing DNA-based anti-malaria vaccines have repeatedly failed to protect ... speed and better inform the development of new treatments ...
... Global leaders are,rediscovering the importance of strong competitive ... in today,s economic,environment, according to a new study ... reveals -- Competitive Intelligence adds value and gains,buy-in ... data,into actionable insights that have a financial impact ...
... older adults need our support.,The pressure of their ongoing ... time and few resources, caregivers are often,forced to ignore ... In addition to their,primary jobs in the workplace and ... role of caregiver to others., Recognizing that caregivers ...
... PRGO ; TASE) today announced that it will ... Tuesday, May 6, 2008 at approximately,8:00 a.m. (ET). The ... hosted by Joseph C. Papa, Perrigo,s Chairman and Chief ... via webcast to interested,parties on the Perrigo website ...
Cached Medicine News:Health News:NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Women's Hair Loss 2Health News:NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Women's Hair Loss 3Health News:The spring in your step is more than just a good mood 2Health News:Discovery to hasten new malaria treatments, vaccines for children 2Health News:Discovery to hasten new malaria treatments, vaccines for children 3Health News:Complimentary Excerpt Available from Best Practices: Pharmaceutical Competitive Intelligence Excellence - Optimizing Data Collection within Approved Guidelines 2Health News:'2008 Caregiving Conferences' Come to Wayne County, Offering Free Workshops and Resources in Canton and Taylor Locations 2
... immunoassay system features an extensive menu, ... and excellent assay performance. The IMMULITE ... onboard dilutions, positive sample identification, and ... 1000 (and its predecessor, the IMMULITE) ...
AIA - Nex.IA immunoassay analyzer state of the art automation and flexibility for high throughput immunoassay testing...
... automated random access immunoassay testing, comes the AIA-600 ... proven reliability of Tosohs original AIA-600, is loaded ... and continuous process operation., Test Menu: ... FT3 FT4 T-Uptake TSH 3rd ...
AutoDelfia is an automatic immunoassay system aimed at larger and medium-sized routine diagnostics or population screening laboratories....
Medicine Products: